Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 7:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Results available

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCT01429454
Conditions
Psychosis
Interventions
Omega-3 Long Chain Fatty Acid, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
12 Years to 30 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • New Haven, Connecticut + 5 more
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effects of Fats on Satiety and Energy Needs

NCT02496936
Conditions
Obesity
Interventions
SFA, MUFA, PUFA-LA, ALA, LCn3
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Conditions
Retinopathy of Prematurity
Interventions
Omegaven, Standard lipids (primarily omega-6 fatty acids)
Drug · Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Conditions
Preterm Birth, Child Development
Interventions
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA), Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
10 Months to 16 Months
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Malnutrition, Child
Interventions
Smoflipid, Intralipid, 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
3 Months to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

SMOFlipid to Lessen the Severity of Neonatal Cholestasis

NCT02721277
Conditions
Cholestasis, Jaundice, Obstructive
Interventions
SMOFlipid
Drug
Lead sponsor
University of Florida
Other
Eligibility
23 Weeks to 1 Year
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Fish Oil and Muscle Function

NCT01308957
Conditions
Sarcopenia
Interventions
Omega-3 fatty acids, corn oil
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 4 Interventional Accepts healthy volunteers

AlmegaPL CV Health Open Label Study

NCT05267301
Conditions
Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions
AlmegaPL (FDA NDIN # 826)
Dietary Supplement
Lead sponsor
Qualitas Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Houston, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults

NCT03043365
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
control fish oil, LCMUFA-rich saury oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Conditions
Infant Development
Interventions
Docosahexaenoic acid (DHA) and arachidonic acid (ARA), Corn oil placebo
Dietary Supplement
Lead sponsor
Retina Foundation of the Southwest
Other
Eligibility
351 Days to 379 Days
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Not listed Phase 2 Interventional Accepts healthy volunteers

n-3 PUFA for Vascular Cognitive Aging

NCT01953705
Conditions
Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
Interventions
Omega 3 PUFA, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
75 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
AKBM-3031, Placebo
Dietary Supplement · Other
Lead sponsor
Aker BioMarine Human Ingredients AS
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

NCT03402789
Conditions
Amblyopia
Interventions
Docosahexaenoic Acid, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland